• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology

    2019-11-05 03:31:32AngelaMweempwaMichelleWilson
    Cancer Drug Resistance 2019年3期

    Angela Mweempwa,Michelle K.Wilson

    Cancer and Blood,Auckland City Hospital,Auckland 1023,New Zealand.

    Abstract

    Poly-adenosine diphosphate ribose polymerase inhibitors (PARPi) lead to synthetic lethality when used in cancers harbouring a BRCA mutation or homologous recombination deficiency.There are now four PARPi approved by the Food and Drug Administration for therapeutic use is ovarian and breast cancer.In addition to this,there is data supporting its use in pancreatic adenocarcinoma and prostate cancer.However,development of resistance to PARPi limits the duration of response.Key mechanisms found to date include:(1) restoration of homologous recombination; (2) changes in PARP1; (3) suppression of non-homologous end joining; (4) replication fork protection; and (5) drug concentration.Gaining a better understanding of resistance mechanisms may guide combination therapies to overcome the resistance and improve the efficacy of PARPi.The purpose of this review is to describe the resistance mechanisms to PARPi and discuss their early detection.

    Keywords: Poly-adenosine diphosphate ribose polymerase inhibition,resistance mechanisms,homologous recombination,BRCA reversion,ovarian cancer

    INTRODUCTION

    Poly-adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitors are now part of mainstream therapy for cancers harbouring BRCA mutations as well as other deficiencies in homologous recombination (HR) repair[1-6].Since 2014,four PARP inhibitors (PARPi) have been approved in the United States:olaparib,niraparib,rucaparib and talazoparib[3,5,7-12][Table 1].Olaparib was the first FDA approved PARPi,initially for recurrent ovarian carcinoma with a germline BRCA mutation exposed to at least 3 lines oftherapy and subsequently as maintenance therapy for women with germline BRCA mutations and patients with breast cancer with germline BRCA mutations[1,2,5,7-9].Veliparib was awarded orphan drug designation for squamous non-small cell lung cancer[13].Although veliparib is the least potent of the PARPi currently in use,there are multiple combination trials in progress such as the S1416 study (NCT02595905)[14].Pamiparib is another PARPi under investigation in a number of clinical trials[15-17].

    Table 1.Current FDA approved PARP inhibitors

    Talazoparib has the greatest PARP trapping activity (rank from highest:talazoparib > niraparib > olaparib = rucaparib > veliparib) and is the most potent among the PARPi in current use[14,18].

    Although nausea,fatigue and anaemia are common to all PARPi,some differences in the toxicity profiles have been observed.Thrombocytopenia is more prominent with niraparib,with grade 3 or 4 reductions in platelet counts occurring in a third of treated patients[3].A retrospective analysis has shown that modifying the dose of niraparib based on baseline body weight and platelet counts may reduce the degree of thrombocytopenia[19].Elevated serum creatinine has been observed with olaparib in 11% of patients whereas both rucaparib and niraparib have been reported to cause an increase in alanine aminotransferase or aspartate aminotransferase[5,10].

    The interest in these agents has expanded and is now being explored in many different cancer types including prostate and pancreatic cancer[20,21].Because the likelihood of relapse is high in these patient populations,defining the mechanisms promoting resistance,and subsequent therapeutic failure remains extremely important.This paper will present the current literature on this.

    MECHANISM OF ACTION OF PARPi

    PARPs are a superfamily of 17 enzymes involved in a multitude of intracellular processes including DNA damage repair,replication and transcription.PARP1 and PARP2 are constitutively expressed but only become activated on binding to sites of DNA damage.PARP1 and PARP2 use nicotinamide adenine dinucleotide (NAD+) as a substrate to transfer ADP-ribosyl groups onto acceptor proteins and produce long poly(ADP-ribose) (PAR) chains in a process called PARylation[22].PARylation of core histones exerts a negative charge and leads to relaxation of chromatin and recruitment of transcription proteins[23].Auto-PARylation of PARP1 and PARP2 permits their dissociation from DNA,a step required for the repair proteins to access damaged DNA[24,25].PARylation is counteracted by the activity of PAR glycohydrolase (PARG)[26].

    PARP1,the most abundant of the PARPs,recognizes DNA single-strand breaks and repairs them by base excision repair (BER).PARPi suppress BER leading to stalling of the replication fork and subsequent development of double-strand breaks (DSBs).In BRCA proficient cells,DSBs are repaired by HR.HR is a DNA repair mechanism that utilises a homologous chromosome or sister chromatid as a template for repair of the damaged portion of DNA[24].During HR,BRCA1 promotes the 5' to 3' resection of DSB with the involvement of nucleases such as MRE11,carboxy-terminal binding protein interacting protein (CtIP) and exonuclease 1,leaving a 3' overhang onto which BRCA2 loads RAD51,enabling invasion of a sister chromatid to be used as a template for DNA repair[27].As a result,this repair pathway is precise and errorfree[24].In contrast,DSBs in BRCA deficient cells are repaired by non-homologous end joining (NHEJ),a process inherently prone to errors as it involves removal of the section containing damaged DNA and ligation of the ends which leads to loss of DNA sequence[24].Errors resulting from NHEJ lead to genomic instability,cell cycle arrest and apoptosis[28].It is widely known that inhibiting PARP in the setting of a BRCA mutation leads to synthetic lethality since it is the combination of a PARPi and BRCA deficiency that induces lethality[29][Figure 1].

    Two mechanisms of action of PARPi have been described.PARPi competitively bind to the NAD+ site of PARP1 and PARP2 resulting in inhibition of their catalytic activity[14,30].When this occurs there is a failure of auto-PARylation of PARP leading to PARP trapping,which may be the main mechanism of action of some PARPi such as talazoparib[31].Although the efficacy of PARPi is higher in cancers with BRCA mutations or HR deficiency (HRD),it is known that they can be beneficial to patients with wild-type BRCA and in the absence of HRD[3].

    RESISTANCE MECHANISMS

    While BRCA 1/2 mutations remain the strongest markers of PARPi sensitivity[3],40%-70% of this patient cohort will fail to respond[32-34].To date,several mechanisms of resistance have been described including :(1) restoration of HR; (2) changes in PARP1; (3) suppression of NHEJ; (4) replication fork protection; and (5) drug concentration [Figure 2].The most common acquired mechanism of resistance appears to be the restoration of BRCA1 or BRCA2 protein function as a result of secondary mutations[28].

    MECHANISMS OF RESISTANCE RELATED TO RESTORATION OF HOMOLOGOUS RECOMBINATION

    There are multiple different pathways that lead to the restoration of HR function.BRCA1 or BRCA2 protein functionality can be restored through the development of intragenic mutations or epigenetic reversions that lead to activation of the open reading frame[27].It is recognised that 46% of recurrent platinum-resistant epithelial ovarian carcinoma develop secondary somatic mutations restoring BRCA1/2 function[35].Additionally,overexpression of BRCA driven by copy number gain and/or upregulation of the remaining functional allele has been shown in tumours with somatic loss of BRCA[36].

    Furthermore,de novointrachromosomal genomic BRCA1 rearrangements and promoter demethylation leading to re-expression of BRCA1 have been demonstrated in PDX models and post-treatment biopsies of triple-negative breast cancer patients,respectively[37].Promoter demethylation may also arise from a heterogeneous tumour in which cells with less promoter methylation undergo positive selection with exposure to PARPi[27].

    Additionally,other proteins involved in the DNA repair process may restore HR.Illustrating this,53BP1 works in close relation with BRCA1 balancing HR and NHEJ repair pathways.53BP1 commits DNA repair to classical-NHEJ by blocking CtIP-mediated DNA end resection[27].The loss of 53BP1 in BRCA deficient cells leads to resection of DNA double-stranded breaks prompting RAD51 recruitment and restoration of HR[38].More recently,new DNA repair factors,including RINN1,RINN2 and RINN3,have been identified which interact with REV7 to form the shieldin complex[39-41].It has been proposed that shieldin functions as a downstream effector of 53BP1-RIF1 in the DNA double-stand break repair pathway,preventing DNA end resection and thus,promoting NHEJ[39].Deletion of any components of the shieldin complex confers resistance to PARPi in BRCA1-mutant cells by re-establishing end resection and restoring HR[28,39].

    Figure 2.Mechanisms of PARPi resistance.A:Efflux of PARP inhibitors by P-gp pumps may contribute to resistance by reducing the intracellular PARPi concentration; B:PARP1 deletion or point mutations in PARP1 reduce sensitivity to PARPi.PARG suppression restores downstream PARP1 signalling with PARPi therapy; C:loss of expression of PTIP,EZH2,MUS81 or increased miR-493-5p results in stabilization of the replication fork,leading to PARPi resistance; D:deficiency of 53BP1,RIF1,REV7 and RINN1-3 involved in the regulation of DNA end-resection during DNA repair may induce PARPi resistance; E:overexpression of miR-622 suppresses NHEJ and rescues the homologous recombination deficiency of BRCA mutated cells.Modified from Thomas et al.[30].PARP1:poly(ADP) ribose polymerase 1; NAD:nicotinamide adenine dinucleotide; PARG:poly(ADP) ribose glycohydrolase; HR:homologous recombination; NHEJ:nonhomologous end joining; DNA:deoxyribonucleic acid

    RAD51 is another protein that plays a key role in HR repair.It is loaded onto single-stranded and doublestranded DNA by BRCA2 to form a protective filament against nucleases[42].An increase in RAD51 will promote HR and subsequently,resistance to PARPi[43].RAD51C and RAD51D are RAD51 paralogs that also play an essential role in DNA repair through HR.The presence of a germline mutation in RAD51C and RAD51D predisposes women to ovarian cancer and is associated with PARPi sensitivity[44].Secondary mutations in RAD51C and RAD51D lead to the restoration of the open reading frame,allowing HR function to proceed which contributes to the development of PARPi resistance[44].PTEN loss in the setting of BRCA1 mutation is another mechanism that leads to reversal of HR deficiency[45].

    Acute myeloid leukaemia driven by transcription factors,AML1-ETO and PML-RARα fusion oncoproteins,is sensitive to PARPi due to suppressed HR and compromised DNA damage response[46].It has been shown that overexpression of the myeloid leukaemia-associated HOXA9 gene in AML1-ETO and PML-RARαtransformed cells enhances HR efficiency leading to PARPi resistance[46].

    Schlafen 11 (SLFN11) expression is another factor that has been shown to correlate with PARPi sensitivity[47,48].It has been suggested that SLFN11 inhibits replication by inducing prolonged cell cycle arrest at S-phase after PARPi treatment,whereas SLFN11-deficient cells are able to continue replicating,resulting in PARPi resistance[47].It is likely over the next 5 years,more genes involved in this process will become recognised as evidence arises.

    RESISTANCE MECHANISMS RELATED TO PARP1

    PARP1 is the most abundant of the PARPs but while it plays a role in multiple intracellular processes,it is not essential to cell survival and PARP1 deletion does not lead to cell death[24].It has been shown that PARP1 deletion leads to partial PARPi resistance,rather than complete because PARP trapping is not the sole mechanism of PARPi action[24,49].Specific point mutations,however,can lead to PARPi resistance as shown withde novoresistance to Olaparib in a patient with ovarian cancer[50].Additionally,PARP1 phosphorylation at Tyr907 by tyrosine kinase c-Met increases PARP1 catalytic activity and reduces binding affinity to PARPi leading to PARPi resistance[51].

    PARG plays a vital role in the degradation of nuclear PAR,preventing its accumulation and counteracting the effects of PARP1[26].It is now recognized that PARG depletion is associated with PARPi resistance in HR deficient tumours by restoring PARP1 signalling[26].

    It remains controversial as to whether overexpression of PARP1 leads to resistance to PARPi.Earlier data suggested that it did lead to resistance resulting in increased PARPi concentrations required to inhibit the enzyme[52].This is in contrast to a retrospective analysis of BRCA1 and PARP1 expression in epithelial ovarian cancer patients that showed no correlation between survival and PARP1 expression[53].

    Suppression of NHEJ

    As described earlier,DSBs can be repaired by NHEJ or HR[24].The balance between HR and classical NHEJ (C-NHEJ) is maintained by miR-622,which limits C-NHEJ and promotes HR.Overexpression of miR-622 is associated with decreased expression of genes such as 53BP1,Ku70,and Ku80[54].The Ku complex normally diverts DNA damage response to the C-NHEJ pathway,therefore its decreased expression will lead to activation of HR by the accumulation of MRE11 foci at the sites of DSBs.This rescues the HR deficiency of BRCA1 mutated cells and induces resistance to PARPi[54].

    Replication fork protection

    BRCA1 and BRCA2 play a critical role in replication fork protection.BRCA1 promotes end resection of DSBs enabling BRCA2 to load RAD51 onto the exposed DNA strands,thus protecting the replication fork from MRE-mediated degradation[27].Stabilization of the replication fork induces alternate mechanisms of DNA repair resulting in PARPi resistance[24].Pax2 transactivation domain-interacting protein (PTIP) is a DNA damage response protein that is required to recruit MRE11 nuclease for replication fork degradation.Deficiency of PTIP impedes the recruitment of the MRE11 nuclease to stalled replication forks,which in turn protects nascent DNA strands from extensive degradation[55].As a result,there is a reduced level of chromosomal aberrations in BRCA1/2 deficient cells,leading to genomic stability and drug resistance[55].

    There is also work demonstrating that EZH2,a histone methyl-transferase,plays a role in replication fork degradation by recruiting nuclease MUS81 to the stalled fork[56].Therefore,loss of expression of EZH2 or MUS81 will lead to PARPi resistance due to the resulting fork stabilization[56].A mi-RNA has been identified,miR-493-5p,that downregulates MRE11,CHD4 and EXO1 in BRCA2 mutant cells and by doing so,preserves replication fork stability[42].It is interesting to note that these mechanisms of resistance leading to replication fork stabilization do not restore HR[42,55,56].

    Drug concentration

    Drug concentration of the PARP inhibitor may play a role.The p-glycoproteins (P-gp),also called multidrug resistance proteins are involved in the efflux of PARPi.Upregulation of ATP-dependent efflux pumpABCB1(MDR1) gene,which encodes for P-glycoprotein,a multidrug efflux transporter,can lead to resistance to some PARPi due to their enhanced extracellular translocation[57].P-gp inhibitors have been shown to prevent the decrease of PARPi in colon cancer cells[58]and re-sensitize PARPi-resistant BRCA-1 deficient cells to PARPi[59].In the mouse models,PARPi was more effective when P-gp knockout conditions were added to BRCA-1 deficient cells[60].More work is needed in this domain because the resistance to PARPi via upregulation of P-gp has mainly been demonstrated in cell and animal models[61].

    Detecting resistance

    Different methods to detect markers of resistance have been explored.Spatial and temporal heterogeneity is a challenge facing personalised medicine in oncology.Ongoing studies are underway exploring the impact of subclonal populations on tumour biology and progression.Serial tumour sampling to monitor clonal evolution poses practical challenges and is currently not standard practice.An alternative approach under investigation is the use of “l(fā)iquid biopsies”,whereby circulating cell-free tumour DNA (cfDNA) or circulating tumour cells (CTCs) are analysed in the peripheral blood of patients with cancer[62].

    The value of cfDNA and serial samples has been investigated in five patients with ovarian cancer with intragenic mutations predicted to restore BRCA1/2 open reading frames,including two patients with multiple independent reversion alleles[63].Reversion mutations were detected only in tumour samples from patients with recurrent disease (5 of 16) and only in cfDNA from three of five patients with a tumourdetected reversion.In this study,findings from a rapid autopsy of one patient with multiple independent reversions demonstrated that reversion-allele frequency in metastatic sites is an important determinant of assay sensitivity.Research continues in this area[63].

    It is important this field continues to be explored and practical methods to delineate mechanisms of resistance continue to be tested such as cfDNA if patient outcomes are to improve.In lung cancer,therapeutic advances have continued to be made for patients with EGFR mutations through improved understanding of the mechanisms of resistance to first-generation tyrosine kinase inhibitors such as erlotinib and the subsequent development of agents specific to the identified mechanisms.This may be more challenging due to the large number of potential mechanisms of resistance to PARPi.Ongoing trials such as the NEO study (NCT03548467) are looking to better identify this.This study uses a window of opportunity design to better delineate predictors of response and resistance to PARPi alongside the use of circulating tumour DNA.ARIEL 2,a phase 2 trial investigating rucaparib in relapsed,platinum sensitive high grade ovarian carcinoma,included the collection of biopsies at relapse to also help delineate this[64].Discovering more about this and identifying practical ways to assess this will help improve care for these patients.

    Overcoming resistance

    The main cause of resistance appears to be through the restoration of HR.Due to the complexity of this pathway,there are multiple changes beyond the restoration of the BRCA1/2 protein that contribute to this.Addition of agents that disrupt HR such as CDK12,CDK1 and PI3K inhibitors are some of the strategies being investigated to overcome this resistance[27].Furthermore,a clinical trial (NCT03742245) has been designed to assess the synergism between histone deacetylase inhibitors and PARPi in BRCA deficient cells[65].Combination with an ATR inhibitor overcomes PARPi resistance resulting from SLFN11 inactivation and is currently being evaluated in a phase I study (NCT02723864)[47].

    There is a host of other clinical trials in progress looking at alternative strategies to maintain sensitivity to PARPi,such as concurrent inhibition of WEE1,VEGFR and mTOR pathways[66].WEE1 is a cell cycle regulator that promotes reversible cell cycle arrest to facilitate DNA repair.WEE1 inhibitors cause the cells to enter S phase with unrepaired DNA and when used in conjunction with PARPi therapy,may mitigate PARPi resistance[66].

    Inhibition of angiogenesis with VEGFR inhibitors induces hypoxia in the tumour microenvironment leading to decreased expression of HR repair proteins and therefore enhanced effects of PARPi therapy[67].Phase 3 trials are in progress exploring this strategy in ovarian cancer by combining olaparib and cediranib,a pan-VEGFR inhibitor (NCT02446600 and NCT02502266).In addition,it has been demonstrated that mTOR inhibitors suppress HR repair and synergize with PARPi which may be another approach to preserve PARPi sensitivity[68].

    CONCLUSION

    PARPi have led to improved outcomes in a several tumour types.The importance of HR deficiency is one key factor in predicting patients that are more likely to be sensitive.The likelihood of relapse remains high in these patient populations,and hence defining the mechanisms promoting resistance,and subsequent therapeutic failure remains extremely important.Gaining an understanding of resistance mechanisms may guide combination therapies to overcome resistance.Choosing the best treatment option following the development of resistance to PARPi remains a challenge.Multiple signatures may predict responders and also non-responders.Given the complexity,ongoing research will help better delineate the cohorts that benefit and help define therapies that overcome resistance pathways.

    DECLARATIONS

    Authors' contributions

    Both authors contributed equally to the article.

    Availability of data and materials

    Not applicable.

    Financial support and sponsorship

    None.

    Conflicts of interest

    Wilson MK has travel support from MSD and Roche,Mweempwa A has travel support from Roche.

    Ethical approval and consent to participate

    Not applicable.

    Consent for publication

    Not applicable.

    Copyright

    ?The Author(s) 2019.

    日日摸夜夜添夜夜添小说| 国产精品免费视频内射| 久久婷婷成人综合色麻豆| 久久99热这里只有精品18| 欧美日韩亚洲综合一区二区三区_| 18禁裸乳无遮挡免费网站照片| 久久草成人影院| 亚洲国产日韩欧美精品在线观看 | 精品久久久久久久久久久久久| 9191精品国产免费久久| 少妇粗大呻吟视频| 久久精品国产清高在天天线| 男女视频在线观看网站免费 | 91麻豆精品激情在线观看国产| 日本a在线网址| xxxwww97欧美| 可以在线观看毛片的网站| 日本黄色视频三级网站网址| 国产欧美日韩一区二区三| 啪啪无遮挡十八禁网站| 色av中文字幕| 又黄又爽又免费观看的视频| 18禁黄网站禁片免费观看直播| 中文字幕熟女人妻在线| 欧美日韩一级在线毛片| 国产激情欧美一区二区| 日本黄大片高清| 国产蜜桃级精品一区二区三区| 男女下面进入的视频免费午夜| 欧美av亚洲av综合av国产av| 成人国产一区最新在线观看| 天天一区二区日本电影三级| 伦理电影免费视频| 日日夜夜操网爽| 在线a可以看的网站| 99国产极品粉嫩在线观看| 日韩欧美三级三区| 欧美成人性av电影在线观看| 青草久久国产| 99久久综合精品五月天人人| 精品高清国产在线一区| 三级国产精品欧美在线观看 | 亚洲中文字幕日韩| 在线观看www视频免费| www.自偷自拍.com| 中文字幕人妻丝袜一区二区| 在线观看美女被高潮喷水网站 | 国产日本99.免费观看| 99热这里只有是精品50| 两性午夜刺激爽爽歪歪视频在线观看 | 一二三四在线观看免费中文在| 我的老师免费观看完整版| 国产男靠女视频免费网站| 婷婷六月久久综合丁香| 国产免费av片在线观看野外av| avwww免费| 国产一区二区在线av高清观看| 视频区欧美日本亚洲| 久久久国产精品麻豆| 亚洲五月天丁香| 给我免费播放毛片高清在线观看| 亚洲五月婷婷丁香| e午夜精品久久久久久久| 久久久久精品国产欧美久久久| 国产探花在线观看一区二区| 特级一级黄色大片| 悠悠久久av| avwww免费| 亚洲男人天堂网一区| 久久久久久大精品| 欧美成人性av电影在线观看| 在线观看午夜福利视频| 中文字幕精品亚洲无线码一区| 国产亚洲欧美98| 日本三级黄在线观看| 国产又黄又爽又无遮挡在线| 亚洲中文日韩欧美视频| 免费观看精品视频网站| 亚洲精品av麻豆狂野| 黑人操中国人逼视频| 日本熟妇午夜| 欧美成人午夜精品| 又粗又爽又猛毛片免费看| 国内少妇人妻偷人精品xxx网站 | 国产精品久久久久久久电影 | 日韩大码丰满熟妇| 最近在线观看免费完整版| 99热6这里只有精品| 精品久久久久久成人av| 免费观看精品视频网站| 9191精品国产免费久久| 国产乱人伦免费视频| 色尼玛亚洲综合影院| 亚洲欧美日韩高清在线视频| 女人爽到高潮嗷嗷叫在线视频| 亚洲欧美日韩东京热| 亚洲精品中文字幕在线视频| 久久国产乱子伦精品免费另类| 两个人免费观看高清视频| 老汉色av国产亚洲站长工具| 亚洲精华国产精华精| 老司机福利观看| 午夜日韩欧美国产| 久久久久久人人人人人| 黄片小视频在线播放| 99国产精品一区二区蜜桃av| 亚洲欧美激情综合另类| 亚洲欧洲精品一区二区精品久久久| 免费无遮挡裸体视频| 91字幕亚洲| 女生性感内裤真人,穿戴方法视频| 久久久久国内视频| 美女扒开内裤让男人捅视频| 欧美性长视频在线观看| 男人舔奶头视频| 亚洲国产欧洲综合997久久,| 午夜福利在线观看吧| 色综合欧美亚洲国产小说| 欧美高清成人免费视频www| 欧美日韩精品网址| av中文乱码字幕在线| 99精品欧美一区二区三区四区| 久久人妻福利社区极品人妻图片| 香蕉国产在线看| 国产精品一区二区免费欧美| 91字幕亚洲| 性色av乱码一区二区三区2| 校园春色视频在线观看| 亚洲电影在线观看av| 久久精品影院6| 久久这里只有精品19| 欧美性长视频在线观看| 国产欧美日韩一区二区三| 好男人在线观看高清免费视频| 波多野结衣巨乳人妻| 亚洲国产精品999在线| 99久久无色码亚洲精品果冻| 免费在线观看日本一区| 午夜影院日韩av| 亚洲aⅴ乱码一区二区在线播放 | 久久精品综合一区二区三区| 老司机午夜福利在线观看视频| 亚洲欧美精品综合一区二区三区| 99在线人妻在线中文字幕| 两人在一起打扑克的视频| 成年版毛片免费区| 天堂√8在线中文| aaaaa片日本免费| 亚洲va日本ⅴa欧美va伊人久久| 国产免费av片在线观看野外av| 男插女下体视频免费在线播放| 国产精品永久免费网站| 欧美高清成人免费视频www| 97碰自拍视频| 大型av网站在线播放| 制服人妻中文乱码| 大型黄色视频在线免费观看| 人成视频在线观看免费观看| 九色国产91popny在线| 好男人电影高清在线观看| 狠狠狠狠99中文字幕| 国产aⅴ精品一区二区三区波| 少妇粗大呻吟视频| 一夜夜www| 伦理电影免费视频| 久久欧美精品欧美久久欧美| 老鸭窝网址在线观看| 国产探花在线观看一区二区| 美女午夜性视频免费| 桃红色精品国产亚洲av| 欧美日韩国产亚洲二区| 91麻豆精品激情在线观看国产| 别揉我奶头~嗯~啊~动态视频| 搞女人的毛片| 天堂动漫精品| 中出人妻视频一区二区| 国产99白浆流出| 亚洲性夜色夜夜综合| 亚洲男人的天堂狠狠| 黄色 视频免费看| 我要搜黄色片| 淫妇啪啪啪对白视频| 亚洲乱码一区二区免费版| 久久亚洲真实| 中文字幕av在线有码专区| 中文字幕人成人乱码亚洲影| 麻豆国产av国片精品| 国产午夜精品论理片| 色综合亚洲欧美另类图片| 女警被强在线播放| 国产精品98久久久久久宅男小说| 露出奶头的视频| 亚洲国产中文字幕在线视频| 老熟妇仑乱视频hdxx| 18禁美女被吸乳视频| 国产在线精品亚洲第一网站| 18禁黄网站禁片免费观看直播| 欧美乱妇无乱码| 亚洲一区二区三区不卡视频| 美女黄网站色视频| www国产在线视频色| 999久久久精品免费观看国产| 99国产综合亚洲精品| 欧美大码av| 日本五十路高清| 18美女黄网站色大片免费观看| 日日夜夜操网爽| 在线观看一区二区三区| 精品无人区乱码1区二区| 国产精品99久久99久久久不卡| 19禁男女啪啪无遮挡网站| 熟女少妇亚洲综合色aaa.| 老汉色∧v一级毛片| 最近最新中文字幕大全免费视频| 精品久久久久久久人妻蜜臀av| 男人舔女人下体高潮全视频| 国产真实乱freesex| 欧美日韩瑟瑟在线播放| 免费高清视频大片| 一级作爱视频免费观看| 亚洲中文日韩欧美视频| 亚洲成人国产一区在线观看| 久久久久国产一级毛片高清牌| 国产一级毛片七仙女欲春2| 51午夜福利影视在线观看| 夜夜躁狠狠躁天天躁| 在线视频色国产色| 欧美人与性动交α欧美精品济南到| 免费在线观看视频国产中文字幕亚洲| 天堂动漫精品| svipshipincom国产片| 亚洲 国产 在线| 午夜福利在线观看吧| 韩国av一区二区三区四区| 99热只有精品国产| 欧美日韩亚洲国产一区二区在线观看| 一级毛片高清免费大全| 丰满人妻一区二区三区视频av | 极品教师在线免费播放| 黄色a级毛片大全视频| 美女大奶头视频| 欧美日韩福利视频一区二区| 亚洲熟女毛片儿| 男女之事视频高清在线观看| 日韩欧美国产在线观看| 日韩 欧美 亚洲 中文字幕| 一级作爱视频免费观看| 熟女电影av网| 日韩av在线大香蕉| 精品久久久久久久人妻蜜臀av| 一进一出好大好爽视频| 性欧美人与动物交配| 人妻夜夜爽99麻豆av| 99国产精品一区二区蜜桃av| 香蕉久久夜色| 国产一区二区在线av高清观看| 亚洲第一电影网av| 欧美在线黄色| 亚洲免费av在线视频| 精品国产亚洲在线| 久久天躁狠狠躁夜夜2o2o| 可以在线观看毛片的网站| 国产蜜桃级精品一区二区三区| 国产亚洲欧美98| 国产高清视频在线播放一区| 在线观看免费日韩欧美大片| 精品福利观看| 性色av乱码一区二区三区2| 国产av麻豆久久久久久久| 少妇被粗大的猛进出69影院| 色av中文字幕| 亚洲国产精品sss在线观看| 亚洲成人久久爱视频| 全区人妻精品视频| av超薄肉色丝袜交足视频| 香蕉久久夜色| 亚洲av电影在线进入| 99热这里只有是精品50| 国内揄拍国产精品人妻在线| 成年女人毛片免费观看观看9| 好男人电影高清在线观看| 久久九九热精品免费| 国产精品国产高清国产av| 嫩草影院精品99| 免费在线观看日本一区| 免费av毛片视频| 欧美成人免费av一区二区三区| 日韩欧美国产一区二区入口| 毛片女人毛片| 国产精品1区2区在线观看.| 丝袜美腿诱惑在线| 99国产精品99久久久久| 天堂√8在线中文| 一本精品99久久精品77| 国产av一区二区精品久久| 久久精品国产99精品国产亚洲性色| 日韩免费av在线播放| 成人手机av| 一级黄色大片毛片| 久久久久久久精品吃奶| 超碰成人久久| 91av网站免费观看| 好看av亚洲va欧美ⅴa在| 亚洲国产欧美人成| 国产av麻豆久久久久久久| 亚洲男人天堂网一区| 丰满人妻熟妇乱又伦精品不卡| 国产精品久久久av美女十八| 可以在线观看的亚洲视频| 亚洲人成网站在线播放欧美日韩| 色精品久久人妻99蜜桃| 国产精品一区二区精品视频观看| 国产成人精品无人区| 又黄又粗又硬又大视频| 亚洲九九香蕉| 欧美日韩国产亚洲二区| 久久中文字幕一级| 亚洲成av人片在线播放无| 国产欧美日韩一区二区三| 精品久久久久久成人av| 国内揄拍国产精品人妻在线| 亚洲国产中文字幕在线视频| 国内揄拍国产精品人妻在线| 校园春色视频在线观看| 日韩精品免费视频一区二区三区| 特大巨黑吊av在线直播| 无遮挡黄片免费观看| 国产成人av教育| 久久婷婷成人综合色麻豆| 男插女下体视频免费在线播放| av福利片在线观看| 精品久久久久久久末码| 变态另类成人亚洲欧美熟女| 国产精品久久视频播放| 又紧又爽又黄一区二区| a在线观看视频网站| 国产精品一区二区精品视频观看| 国产精品久久久久久人妻精品电影| 国产亚洲精品av在线| 久久香蕉国产精品| 国内精品久久久久精免费| 久久久久久久久久黄片| 日本一本二区三区精品| 精品乱码久久久久久99久播| 淫妇啪啪啪对白视频| 欧美黄色片欧美黄色片| 50天的宝宝边吃奶边哭怎么回事| 深夜精品福利| 国产99久久九九免费精品| 欧美黑人欧美精品刺激| 国产99久久九九免费精品| 亚洲精品美女久久久久99蜜臀| 中文字幕最新亚洲高清| 国产精品免费一区二区三区在线| 观看免费一级毛片| 国产成年人精品一区二区| 久久国产精品人妻蜜桃| 亚洲熟妇中文字幕五十中出| 成人欧美大片| 欧美一区二区国产精品久久精品 | 美女黄网站色视频| 国产成人av激情在线播放| 欧美黑人欧美精品刺激| 窝窝影院91人妻| 久久香蕉国产精品| 亚洲午夜理论影院| 黄频高清免费视频| www日本在线高清视频| 性色av乱码一区二区三区2| 亚洲自偷自拍图片 自拍| 在线观看美女被高潮喷水网站 | 亚洲精品美女久久av网站| 亚洲欧美日韩高清在线视频| 久久久久久国产a免费观看| 窝窝影院91人妻| 久久久水蜜桃国产精品网| 怎么达到女性高潮| 久久久国产精品麻豆| 男男h啪啪无遮挡| 国产精品爽爽va在线观看网站| 国产亚洲精品综合一区在线观看 | 亚洲精品一卡2卡三卡4卡5卡| 欧美黑人巨大hd| 亚洲专区国产一区二区| 久久性视频一级片| 欧美一区二区精品小视频在线| 精品欧美国产一区二区三| 熟女电影av网| 别揉我奶头~嗯~啊~动态视频| 久久久久久九九精品二区国产 | 日韩 欧美 亚洲 中文字幕| 亚洲精品国产一区二区精华液| 国产精品av视频在线免费观看| 国内久久婷婷六月综合欲色啪| 国产精品久久久人人做人人爽| 中文在线观看免费www的网站 | 国产亚洲精品av在线| 精品国产乱码久久久久久男人| 两性午夜刺激爽爽歪歪视频在线观看 | 久久久久久久久免费视频了| 麻豆国产97在线/欧美 | 亚洲av成人av| 日韩欧美在线乱码| 亚洲av第一区精品v没综合| 激情在线观看视频在线高清| 麻豆av在线久日| 亚洲电影在线观看av| 99在线视频只有这里精品首页| 日本免费一区二区三区高清不卡| 国产视频内射| 午夜a级毛片| 正在播放国产对白刺激| 天堂动漫精品| 9191精品国产免费久久| 国产成人精品久久二区二区91| 欧美精品亚洲一区二区| 欧美成狂野欧美在线观看| 国产精品综合久久久久久久免费| 精品无人区乱码1区二区| 亚洲自拍偷在线| 99久久99久久久精品蜜桃| 制服丝袜大香蕉在线| 成人国产综合亚洲| 禁无遮挡网站| 999久久久国产精品视频| 非洲黑人性xxxx精品又粗又长| 午夜福利在线在线| 精品午夜福利视频在线观看一区| 草草在线视频免费看| 国产高清videossex| 久久久久久久久久黄片| 中文字幕高清在线视频| 亚洲七黄色美女视频| 国内精品一区二区在线观看| 在线观看午夜福利视频| 老熟妇仑乱视频hdxx| 两人在一起打扑克的视频| 国产真人三级小视频在线观看| 欧美国产日韩亚洲一区| 国产av又大| 999精品在线视频| 国产精品美女特级片免费视频播放器 | 亚洲真实伦在线观看| 欧美一级毛片孕妇| 亚洲,欧美精品.| 国产精品电影一区二区三区| 我要搜黄色片| 日本成人三级电影网站| 免费在线观看黄色视频的| 亚洲真实伦在线观看| 欧美日韩亚洲国产一区二区在线观看| 在线免费观看的www视频| 久久 成人 亚洲| 欧美日韩亚洲综合一区二区三区_| 欧美激情久久久久久爽电影| 青草久久国产| 国产av在哪里看| 欧美另类亚洲清纯唯美| 日韩欧美三级三区| 中文字幕av在线有码专区| 男女之事视频高清在线观看| 中文亚洲av片在线观看爽| 久久香蕉激情| 久久人人精品亚洲av| www.精华液| 国产高清视频在线观看网站| 搡老熟女国产l中国老女人| 国产成人精品无人区| 亚洲熟女毛片儿| 亚洲人与动物交配视频| 午夜福利欧美成人| 久久久久久久久免费视频了| 欧美性猛交╳xxx乱大交人| 欧美激情久久久久久爽电影| 亚洲色图 男人天堂 中文字幕| 又粗又爽又猛毛片免费看| 精品午夜福利视频在线观看一区| 亚洲av美国av| 国产午夜精品论理片| 午夜福利在线观看吧| 国产高清视频在线播放一区| 老司机午夜福利在线观看视频| 国产欧美日韩一区二区三| 国产av麻豆久久久久久久| 黄频高清免费视频| 欧美三级亚洲精品| 久久久久性生活片| 国产免费av片在线观看野外av| 啦啦啦韩国在线观看视频| 黄色视频,在线免费观看| 色老头精品视频在线观看| 嫁个100分男人电影在线观看| 18禁观看日本| 色综合欧美亚洲国产小说| 岛国视频午夜一区免费看| 真人做人爱边吃奶动态| 亚洲一码二码三码区别大吗| 麻豆久久精品国产亚洲av| 亚洲一区高清亚洲精品| 国产精品免费一区二区三区在线| netflix在线观看网站| 久久久久久久精品吃奶| 99久久久亚洲精品蜜臀av| 成人国语在线视频| 欧美黄色片欧美黄色片| 亚洲一区二区三区不卡视频| 午夜免费激情av| 此物有八面人人有两片| 亚洲精品国产一区二区精华液| 国产成年人精品一区二区| 国产亚洲精品av在线| a级毛片在线看网站| 亚洲电影在线观看av| 久久这里只有精品19| 亚洲片人在线观看| 国产探花在线观看一区二区| 露出奶头的视频| 欧美乱色亚洲激情| 亚洲av日韩精品久久久久久密| 久久久久久国产a免费观看| 国产精品 欧美亚洲| 色在线成人网| 成人三级做爰电影| 在线观看一区二区三区| 精品久久久久久成人av| 国产蜜桃级精品一区二区三区| √禁漫天堂资源中文www| 婷婷六月久久综合丁香| 精品久久久久久久久久久久久| 国产免费av片在线观看野外av| 正在播放国产对白刺激| 免费av毛片视频| 最近最新中文字幕大全电影3| 岛国视频午夜一区免费看| 欧美一级a爱片免费观看看 | 国内精品久久久久久久电影| 国产精品久久久久久亚洲av鲁大| 美女 人体艺术 gogo| 亚洲av成人不卡在线观看播放网| 一进一出抽搐动态| av天堂在线播放| 国产69精品久久久久777片 | 国产91精品成人一区二区三区| 中文在线观看免费www的网站 | 高潮久久久久久久久久久不卡| 九色成人免费人妻av| 99久久99久久久精品蜜桃| 制服丝袜大香蕉在线| 国产99久久九九免费精品| 久久99热这里只有精品18| 高清在线国产一区| 免费av毛片视频| 制服人妻中文乱码| 中文字幕人妻丝袜一区二区| 日日摸夜夜添夜夜添小说| 精品久久久久久久毛片微露脸| 搡老熟女国产l中国老女人| 日本a在线网址| 黄色成人免费大全| 亚洲成av人片免费观看| 一进一出抽搐gif免费好疼| 狂野欧美白嫩少妇大欣赏| 2021天堂中文幕一二区在线观| 人妻久久中文字幕网| 免费av毛片视频| 人妻丰满熟妇av一区二区三区| 亚洲熟妇熟女久久| 91在线观看av| 黄频高清免费视频| 国产精品1区2区在线观看.| 在线观看免费日韩欧美大片| 国产高清视频在线播放一区| 在线看三级毛片| 午夜影院日韩av| 九色国产91popny在线| 51午夜福利影视在线观看| 久久久久久九九精品二区国产 | 麻豆国产97在线/欧美 | 亚洲一码二码三码区别大吗| 国内少妇人妻偷人精品xxx网站 | 午夜两性在线视频| 久久久久国产一级毛片高清牌| 19禁男女啪啪无遮挡网站| 国语自产精品视频在线第100页| 亚洲欧美激情综合另类| 五月玫瑰六月丁香| 国产乱人伦免费视频| 国内精品久久久久久久电影| 亚洲精品色激情综合| 婷婷亚洲欧美| 热99re8久久精品国产| 宅男免费午夜| 欧美 亚洲 国产 日韩一| 真人一进一出gif抽搐免费| 久久亚洲精品不卡| 久久精品国产综合久久久| 制服诱惑二区| 国产又色又爽无遮挡免费看| 亚洲国产欧美网| 91国产中文字幕| av欧美777| 国产亚洲精品一区二区www| 久久香蕉激情| 亚洲激情在线av| 在线十欧美十亚洲十日本专区| 无人区码免费观看不卡| 亚洲av美国av| 午夜激情av网站| 欧美3d第一页| 亚洲精品美女久久av网站| 亚洲色图av天堂| 国产亚洲欧美98| 久久香蕉国产精品| 成人特级黄色片久久久久久久| 欧美日韩亚洲国产一区二区在线观看|